The Clinical Debates
|
|
- Lawrence Greene
- 6 years ago
- Views:
Transcription
1 The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University of Iowa College of Pharmacy. He has completed a residency in primary care at the VA Medical Center in Iowa City. He currently works as a clinical pharmacy specialist at the VA Medical Center in Iowa City and is Assistant Professor at the University of Iowa. Clinical areas include primary care, lipid, and anticoagulation. Douglas Geraets, PharmD, obtained his BSc degree in Pharmacy from South Dakota State University and his post-bs Doctor of Pharmacy degree from the University of Tennessee. Following this he completed a oneyear post-pharmd clinical residency in Adult Internal Medicine at the City of Memphis Hospital. In addition, he completed a Research Fellowship in cardiology at the Ohio State University. He has held faculty positions at the Ohio State University, the University of Missouri at Kansas City, and the University of Iowa. Currently he is Clinical Pharmacy Specialist in Ambulatory Care at the VA Medical Center in Iowa City and Adjunct Professor at the University of Iowa College of Pharmacy. He co-manages the VA s ~1200 patient anticoagulation clinic, is a provider in the ICVA s pharmacist-managed lipid clinic, and provides pharmaceutical care to a variety of other general medicine patients. He has published numerous research and clinical papers, is active in several pharmacy organizations (IPA, ACCP, and ASHP) and is a Fellow of the American College of Clinical Pharmacy. His main pharmacotherapeutic interests include cardiovascular disease, anticoagulation, and dyslipidemia. Dr. Geraets research interests include issues of anticoagulation therapy particularly warfarin effectiveness and safety and clinical management of dyslipidemia. Speaker Disclosures: Matt Cantrell and Doug Geraets report they have no actual or potential conflicts of interest in relation to this program. The speakers have indicated that off-label use of medications will be discussed during this presentation.
2 Statins for Primary Prevention of CVD Faculty Disclosure Dr. Cantrell & Geraets have no actual or potential conflicts of interest associated with this presentation. Dr. Cantrell & Geraets have indicated that no off-label use of medication will be discussed during this presentation. Douglas R. Geraets, Pharm.D., FCCP Clinical Pharmacy Specialist AmCare VA Medical Center Iowa City, IA & Matthew Cantrell, Pharm.D., BCPS Clinical Pharmacy Specialist AmCare VAMC Iowa City, IA Clinical Assistant Professor UI College of Pharmacy Learning Objectives Upon completion of this program pharmacists (or pharmacy technicians) will be able to: Discuss the incidence and general trends for CVD and CVD risk factors in the U.S. population. Describe results from primary prevention studies including Jupiter and how this information applies to primary prevention with statins. Select statements that describe pros & cons of statin use in primary prevention. Patient Case 48 year old male Past Medical History: GERD Osteoarthritis Impaired fasting glucose Gout Social History: ½ pack per day smoker 4-6 beers per week Family History: Non-contributory Medications: Lansoprazole 30 mg daily APAP 500 mg two tabs twice daily Febuxostat (Uloric ) 40 mg daily Laboratory Results: Total Chol. 200 mg/dl LDL 128 mg/dl HDL 45 mg/dl Triglycerides 135 mg/dl ALT 28 IU/L AST 32 IU/L Scr 1.3 mg/dl Fast. glucose 112 mg/dl hs-crp 2.3 mg/l Vital signs: BP 128/75 mm Hg, HR 72, Resp. 20, Temp C Body Mass Index: year CHD risk Framingham=11% Reynolds=5% Pre-Assessment Questions Q. Would you recommend this patient take a statin for primary prevention of CVD? Magnitude of the Problem: Atherosclerotic CVD Leading cause of death for both men and women in the U.S. Mortality decline in last several decades; slowing of decline in 90 s-00 s If all major CVD eliminated, life expectancy 7 years Long asymptomatic latent period
3 Risks for CVD Annual Number (in Thousands) of New Cases of Diagnosed Diabetes Among Adults Aged Years, United States, Increasing Prevalence (%) of Metabolic Syndrome Among U.S. Adults NHANES III ( 88-94) NHANES ( 99-00) Unadjusted Age-Adjusted Ford ES, et al. Diabetes Care October 2004;27(10): Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Treatment vs. Prevention Current algorithms for preventing CVD events/death: statins for patients with established CVD, DM, overt hyperlipidemia ½ of MI/CVA occur among apparently healthy men/women with LDL-C below treatment thresholds Atherosclerosis starts early progresses continually throughout life If individual has an event then we do something about it! Patients want prevention of first event Prevention of CVD Nine modifiable risk factors account for ~90% of initial MI risk 1. Elevated cholesterol 2. Smoking 3. Psychosocial events 4. Hypertension 5. Abdominal obesity 6. DM 7. Unhealthy diet 8. Excessive alcohol 9. Lack of exercise Attributes of Ideal Agent for Primary Prevention CVD Easy to take Affordable Highly effective (surrogate vs. hard endpoints) Well-tolerated No or limited drug-drug, drug-disease, drug-diet interactions Statins in CVD Prevention In recent years large clinical trials of statins in relatively low-risk groups Without CVD With CVD risk factors Low levels LDL-C WOSCOPS, AFCAPS/TexCAPS, PROSPER, ALLHAT-LLT, ASCOT-LLA, HPS, CARDS, ASPEN, MEGA, and JUPITER
4 Estimated 5-YR NNT for Primary Prevention of CVD Trial Population Endpt 5-YR NNT WOSCOPS (lovastatin) AFCAPS (pravastatin) JUPITER (rosuvastatin) Hypercholesterolemia Average cholesterol Low LDL, hscrp MI, stroke, any death 86 MI & cardiac death 44 MI, stroke, death 29 Ridker PM, et al. Circ Cardiovasc Qual 2009; 2: Estimated 5-YR NNT for Primary Prevention of CVD Among Middle-Aged Populations Intervention Population Endpt 5-YR NNT Rosuvastatin Low LDL, hscrp MI, stroke, death 29 Diuretics Hypertension MI, stroke, any 86 death -blockers Hypertension Fatal/nonfatal CHD 140 and stroke Aspirin Men; Women MI, stroke, CV death 346; 426 Ridker PM, et al. Circ Cardiovasc Qual 2009; 2: Summary of Statin Tolerance in Recent Primary Prevention Studies (versus placebo) Parameter WOSCOP (Pravastatin) AFCAPS/ TexCAPS (Lovastatin) ASCOT-LLA (Atorvastatin) JUPITER (Rosuvastatin) Withdrawals N/R No Difference N/R No Difference Myopathic Event No Difference No Difference N/R No Difference CK 10X ULN No Difference No Difference No Difference No Difference AST/ALT 10X ULN No Difference No Difference No Difference No Difference SAE N/R No Difference No Difference No Difference N/R = Not Reported; SAE = Serious Adverse Events Summary Progressing from secondary prevention to primary prevention CVD Statins with many attributes of ideal primary preventive agent Rosuvastatin in primary prevention (CVD) with better NNT values than other CVD preventive therapy Three-quarters of the patients taking statins are taking them for primary prevention. (Arch Int Med 2010; 170(12): )?
5 Reasons to consider judicious use of statins for primary prevention 1. Limited benefits in all-cause mortality 2. JUPITER trial & limitations 3. Adverse effects of statin therapy 4. Pharmacoeconomics Established indications for statins In patients with & without established CHD, statins: Reduce risk of MI, stroke, revasc. procedures, & angina In patients with type 2 DM & other CV risk factors Reduce the risk of MI and stroke Slow progression of atherosclerosis High risk patients receive the most benefits Primary prevention vs. secondary prevention Absolute risk reduction vs. relative risk reduction Statin therapy & all cause mortality Relationship between age and all cause mortality rates in primary prevention statin trials 11 randomized clinical trials 65,229 patients without CHD Statin (32,623) Placebo (N=32,606) Risk Ratio 95% CI All cause death 1,346 (4.1%) 1,447 (4.4%) 0.91 ( ) Participant age at baseline accounted for an estimated 66% of the variation in mortality rates The clinical utility of statins to reduce non-fatal MI and stroke is not in question Ray et al. Arch Int Med. 2010;170(12): Ray et al. Arch Int Med. 2010;170(12): Effect of statins on all-cause mortality in primary prevention randomized controlled trials JUPITER Subjects w/o CV disease with baseline LDL <130 mg/dl & CRP >2.0 mg/l Rosuvastatin (Crestor ) 20 mg vs. placebo Primary endpoint Composite nonfatal MI & stroke, hospit. for unstable angina, arterial revasc., CV death Ray et al. Arch Int Med. 2010;170(12): % relative risk reduction in primary endpoint 142 vs. 251 events (p< ) Ridker et al. NEJM 2008;359(21):
6 JUPITER Absolute risk reduction 0.59 events/100 person years NNT=95 for 2 years Adverse effects: myopathy CK elevation >10,000 U/L RHABDO Frequency 1/10,000 Limitations 1.Excluded those with poor compliance 2.Not so low risk? 3.Generalizability? 4.Role of CRP as biomarker? 5.Potential biases >1,000 U/L Normal or increased None MYOPATHY MYALGIA 1/1, % Cases / 100,000 person years Adverse effects: dose related transaminase elevations with statin therapy Overall risk is approximately 1.3% 10 mg 80 mg Atorvastatin dose Potential adverse effects: Diabetes? 13 randomized trials of 91,140 participants Statin use resulted in 9% increased risk of diabetes (OR = 1.09, 95% CI = ) Number needed to harm (NNH) was 255 Statin therapy for 4 years to produce 1 additional case of diabetes Cases of diabetes in JUPITER 270 (3.0%) vs. 216 (2.4%) (P = 0.01) Sattar et al. Lancet 2010;375(9716): Pharmacoeconomics 80% of middle-aged & elderly would meet criteria for statin therapy Rosuvastatin 20 mg $1,200 annually NNT to prevent 1 primary endpoint 95 for 2 years x $1,200 =$228,000 Costs associated with screening those not eligible Patient Case 48 year old male Past Medical History: GERD Osteoarthritis Impaired fasting glucose Gout Social History: ½ pack per day smoker 4-6 beers per week Laboratory Results: Total Chol. 200 mg/dl LDL 128 mg/dl HDL 45 mg/dl Triglycerides 135 mg/dl ALT 28 IU/L AST 32 IU/L Scr 1.3 mg/dl Fast. glucose 112 mg/dl hs-crp 2.3 mg/l Where are health care dollars best spent? Treating a low risk, asymptomatic population? Targeting high risk secondary prevention patients where gains are statistically & clinically significant Family History: Non-contributory Medications: Lansoprazole 30 mg daily APAP 500 mg two tabs twice daily Febuxostat (Uloric ) 40 mg daily Vital signs: BP 128/75 mm Hg, HR 72, Resp. 20, Temp C Body Mass Index: year CHD risk Framingham=11% Reynolds=5%
7 Would you recommend this patient take a statin for primary prevention? 1. Yes 2. No 50% 50% 1 2
8 Baseline LDL and follow up in primary prevention trials comparing statin therapy to placebo Trial; Intervention (follow up) N; (age) Baseline & Follow up LDL (mg/dl) Event rate per 1000 Person years Comment ASCOT LLA (2003) atorvastatin 10 mg (3.3 yrs) 131 8,715; (63) T: 90 P: 126 T: 10.9 P: % in non fatal MI & CV death; 27% in strokes; All cause mortality non significantly reduced 13% WOSCOPS (1995) pravastatin 40 mg (4.9 yrs) 192 5,981; (55) T: 142 P: 192 T: 6.4 P:8.2 22% reduction in total mortality (not significant (P=0.051); 5.5% vs. 7.9% event rate (p<0.001) ALLHAT (2002) pravastatin 40 mg (4.8 yrs) 148 8,880; (66) T: 105 P: 129 T: 24.3 P: 24.3 No difference in total mortality or CHD event rate AFCAPS /TexCAPS (1998) lovastatin mg (5.2 yrs) 6,605; (58) 150 T: 114 P: 156 T: 4.6 P: % in CV events (fatal and nonfatal MI, unstable angina, or sudden cardiac death; No difference in total mortality HYRIM (2005) fluvastatin 40 mg (4.0 yrs) ; (57) T: 117 P: 136 T: 3.5 P: 4.4 CARDS (2004) atorvastatin 10 mg (4.0 yrs) 2,838; (62) 117 T: 81 P: 120 T: 10.7 P: % of subjects had Type 2 DM 37% reduction in primary endpoint JUPITER (2008) rosuvastatin 20 mg (2.2 yrs) 17,802 (66) 108 T: 54 P: 108 T: 12.5 P: % relative risk reduction in primar endpoint MEGA (2006) pravastatin mg (4.6 yrs) 7,832 (58) 156 T: 128 P: 151 T: 2.4 P: % Japanese population; Event Rate 3.3 vs. 5.5% (p=0.01) Adapted with permission from: Ray et al. Arch Intern Med. 2010;170(12):
9 PREVEND IT (2004) pravastatin 40 mg (3.8 yrs) 864; (51) 154 T: 120 P: 158 T: 7.7 P: 7.2 ASPEN (2006) atoravastatin 10 mg (4.3 yrs) 1,905; (61) 114 T: 79 P: 114 T: 10.8 P: % of subjects had Type 2 DM PROSPER (2002) pravastatin 40 mg (3.2 yrs) 3,239 (75) 146 T: 96 P: 143 Cumulative 65, (62) T: 94 P: 134 T=subjects randomized to treatment with statin, T: 27.2 P: 26.0 T: 10.7 P: 11.4 P=subjects randomized to treatment with placebo Relationship between baseline age of participants and all cause mortality rates in primary prevention trials Adapted with permission from: Ray et al. Arch Intern Med. 2010;170(12):
10 Effect of statin therapy on all cause mortality in primary prevention trials Adapted with permission from: Ray et al. Arch Intern Med. 2010;170(12):
ATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationStatin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines
Drugs Aging (2015) 32:87 93 DOI 10.1007/s40266-014-0238-5 CURRENT OPINION Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Yitzchak Weinberger Benjamin H. Han Published
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors () Final Report June 2004 Mark Helfand, MD, MPH Susan Carson, MPH Cathy Kelley, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationLipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011
Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More information